A Multicenter, Randomized, Placebo-controlled, Parallel Group, Double Blind, Dose-finding Phase II Trial to Study the Efficacy, Safety, Pharmacokinetic and Pharmacodynamic Effects of the Oral Partial Adenosine A1 Receptor Agonist Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction
A Multicenter, Randomized, Placebo-controlled, Parallel Group, Double Blind, Dose-finding Phase II Trial to Study the Efficacy, Safety, Pharmacokinetic and Pharmacodynamic Effects of the Oral Partial Adenosine A1 Receptor Agonist Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction
The objective of the study is to find the optimal dose of once daily oral neladenoson bialanate (BAY 1067197) when given in addition to standard therapy for heart failure with reduced ejection fraction (HFrEF).
Inclusion Criteria:
Exclusion Criteria:
Bad Oeynhausen, North Rhine-Westphalia 32545, Germany
Ludwigshafen am Rhein, Rhineland-Palatinate 67063, Germany
Kifisia / Athens, Attica 14561, Greece
Nea Ionia / Athens, 142 33, Greece
Zrifin, 6093000, Israel
Higashiibaraki, Ibaraki 311-3193, Japan
Itabashi-ku, Tokyo 173-8610, Japan
Shinjuku-ku, Tokyo 162-8666, Japan
Santiago de Compostela, A Coruña 15706, Spain